Cellyan Biotechnology Co., Ltd (HKPD)

Cellyan Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Net Income	-0.7	-0.03	1.33	1
Depreciation & Amortization	1.09	1.07	0.93	0.71
Other Adjustments	-0.03	0.04	-0	-
Change in Receivables	-0.21	-0.92	-2.05	-0.93
Changes in Inventories	-0.04	0.38	-0.74	-0.19
Changes in Accounts Payable	-0.57	0.4	-0.11	0.96
Changes in Income Taxes Payable	-0.22	-0.11	0.2	0.02
Changes in Unearned Revenue	0.45	-0.07	-0.08	0.21
Changes in Other Operating Activities	-0.25	-0.19	0.13	-0.05
Operating Cash Flow	-0.43	0.57	-0.39	1.73
Capital Expenditures	-0.06	-0.07	-0.05	-0.11
Sale of Property, Plant & Equipment	-	-	0.03	-
Purchases of Intangible Assets	-0.03	-0.09	-0.04	-0
Purchases of Investments	-	-2.3	-	-
Other Investing Activities	-	-	0.01	-0.01
Investing Cash Flow	-2.39	-2.45	-0.04	-0.13
Long-Term Debt Issued	1.93	1.59	2.14	0.19
Long-Term Debt Repaid	-1.38	-1.51	-0.92	-0.73
Net Long-Term Debt Issued (Repaid)	0.55	0.08	1.22	-0.54
Issuance of Common Stock	0.05	4.3	0.51	-
Net Common Stock Issued (Repurchased)	0.05	4.3	0.51	-
Other Financing Activities	-1.96	-2.38	-1.19	-0.61
Financing Cash Flow	2.64	2	0.54	-1.16
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.01	0.01	0	0
Net Cash Flow	-0.17	0.12	0.1	0.44
Free Cash Flow	-0.49	0.5	-0.45	1.61
FCF Margin	-3.01%	2.46%	-2.68%	12.84%
Free Cash Flow Per Share	-0.05	0.05	-0.06	0.24
Levered Free Cash Flow	0.26	1.45	2.82	2
Unlevered Free Cash Flow	-0.2	1.3	1.67	2.56

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q